These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32770711)

  • 1. Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid efficiently treated with omalizumab.
    Garrido PM; Alexandre MI; Travassos AR; Filipe P
    Dermatol Ther; 2020 Nov; 33(6):e14160. PubMed ID: 32770711
    [No Abstract]   [Full Text] [Related]  

  • 2. Epitope-spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
    García-Díez I; España A; Iranzo P
    Br J Dermatol; 2019 May; 180(5):1267-1268. PubMed ID: 30675718
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and immunological characterization of 14 cases of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: a single-centre study.
    Hayashi M; Tsunoda T; Sato F; Yaguchi Y; Igarashi M; Izumi K; Nishie W; Ishii N; Okamura K; Suzuki T; Hashimoto T
    Br J Dermatol; 2020 Mar; 182(3):806-807. PubMed ID: 31498425
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of dipeptidyl peptidase-4 inhibitor-related anti-BP230-type bullous pemphigoid showing granular C3 dermatosis-like direct immunofluorescence staining.
    Hashimoto T; Tsunoda T; Arai Y; Izumi K; Ishii N; Qian H; Li X; Tsuruta D
    Eur J Dermatol; 2022 Jul; 32(4):549-551. PubMed ID: 36301770
    [No Abstract]   [Full Text] [Related]  

  • 5. Acquired Haemophilia A in DPP4 Inhibitor-induced Bullous Pemphigoid as Immune Reconstitution Syndrome.
    Sugiyama S; Tanaka R; Hayashi H; Izumi K; Nishie W; Aoyama Y
    Acta Derm Venereol; 2020 Jun; 100(13):adv00178. PubMed ID: 32494825
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients.
    Mai Y; Nishie W; Izumi K; Yoshimoto N; Morita Y; Watanabe M; Toyonaga E; Ujiie H; Iwata H; Fujita Y; Nomura T; Sato-Matsumura KC; Shimizu S; Shimizu H
    Br J Dermatol; 2018 Sep; 179(3):790-791. PubMed ID: 29624639
    [No Abstract]   [Full Text] [Related]  

  • 7. Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading.
    Takama H; Yoshida M; Izumi K; Yanagishita T; Muto J; Ohshima Y; Nishie W; Shimizu H; Akiyama M; Watanabe D
    Acta Derm Venereol; 2018 Nov; 98(10):983-984. PubMed ID: 30085319
    [No Abstract]   [Full Text] [Related]  

  • 8. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid showing positive autoantibody responses to multiple epitopes.
    Kitao R; Fukumoto T; Hashimoto T; Izumi K; Jimbo H; Takemori C; Nishigori C
    J Dermatol Sci; 2021 Sep; 103(3):190-192. PubMed ID: 34489165
    [No Abstract]   [Full Text] [Related]  

  • 9. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: the importance of the pharmacotherapeutic history.
    García-Gil MF; Lezcano Biosca V; García García M; Monte Serrano J; Aldea Manrique B
    Postgrad Med J; 2021 Jan; 97(1143):51-52. PubMed ID: 32198232
    [No Abstract]   [Full Text] [Related]  

  • 10. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
    García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
    Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case of dipeptidyl peptidase 4 inhibitor-associated bullous pemphigoid that developed after a scabies infestation.
    Iriki H; Adachi T; Matsuda H; Chinen K; Arakawa H; Yamagami J; Nishie W; Yokouchi M
    J Dermatol; 2020 Jul; 47(7):e258-e260. PubMed ID: 32415680
    [No Abstract]   [Full Text] [Related]  

  • 12. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of dipeptidyl-peptidase 4 inhibitor-associated pemphigoid nodularis.
    Tahara J; Ono S; Nomura T; Kaku Y; Egawa G; Dainichi T; Izumi K; Nishie W; Honda T; Kabashima K
    Int J Dermatol; 2021 Sep; 60(9):1159-1160. PubMed ID: 33660842
    [No Abstract]   [Full Text] [Related]  

  • 14. Dipeptidyl Peptidase-4 Inhibitor Induced Bullous Pemphigoid Complicated by Acquired Reactive Perforating Dermatosis.
    Gambichler T; Espey B; Doerler M; Stranzenbach R
    Actas Dermosifiliogr; 2022 Oct; 113(9):914-915. PubMed ID: 35636509
    [No Abstract]   [Full Text] [Related]  

  • 15. Βullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?
    Patsatsi A; Kyriakou A; Meltzanidou P; Trigoni A; Lamprou F; Kokolios M; Giannakou A
    Eur J Dermatol; 2018 Oct; 28(5):711-713. PubMed ID: 30325322
    [No Abstract]   [Full Text] [Related]  

  • 16. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
    Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
    J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases.
    Yoshiji S; Murakami T; Harashima SI; Ko R; Kashima R; Yabe D; Ogura M; Doi K; Inagaki N
    J Diabetes Investig; 2018 Mar; 9(2):445-447. PubMed ID: 28520234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.
    Horikawa H; Kurihara Y; Funakoshi T; Umegaki-Arao N; Takahashi H; Kubo A; Tanikawa A; Kodani N; Minami Y; Meguro S; Itoh H; Izumi K; Nishie W; Shimizu H; Amagai M; Yamagami J
    Br J Dermatol; 2018 Jun; 178(6):1462-1463. PubMed ID: 29478242
    [No Abstract]   [Full Text] [Related]  

  • 19. Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Iwamoto Y; Anno T; Koyama K; Kawasaki F; Kaku K; Tomoda K; Sugiyama S; Aoyama Y; Kaneto H
    Front Immunol; 2022; 13():843480. PubMed ID: 35309321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid.
    Lindgren O; Varpuluoma O; Tuusa J; Ilonen J; Huilaja L; Kokkonen N; Tasanen K
    Acta Derm Venereol; 2019 May; 99(6):602-609. PubMed ID: 30848289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.